Neogen Now Expects Regulators To Finish Zoetis Genomics Deal Review In Early 2027
Zoetis offered to divest certain Australian assets to ease clearance of its purchase of Neogen's global Genomics business.
Neogen, which makes food safety and animal safety test kits and related products, said in an 8-K filing on Wednesday that it expects regulatory review of the sale of its global Genomics business to Zoetis to conclude in early 2027. The timeline follows an offer by Zoetis to divest certain assets in Australia.
Australian assets on the table
Zoetis has recently offered to sell certain assets in Australia to help the clearance process, Neogen said. Because of that offer, the company wrote, it expects the review to wrap up in early 2027.
Neogen and Zoetis are continuing to cooperate with the Australian Competition and Consumer Commission and the New Zealand Commerce Commission, whose reviews of the transaction are ongoing.
A deal first announced in March
Neogen announced on March 2, 2026 that it had signed a definitive agreement to sell its global Genomics business to Zoetis. The transaction remains subject to customary closing conditions and regulatory approvals.
Genomics sits inside Neogen's Animal Safety segment, which also sells veterinary instruments, pharmaceuticals, vaccines, rodent and insect control products and drug detection tests, mainly through veterinarians, retailers, livestock producers and distributors. The other segment, Food Safety, sells diagnostic test kits, culture media and software to food and feed producers, processors, laboratories and regulators.
The conclusions of the Australian and New Zealand regulators, which Neogen expects in early 2027, now set the pace for the sale.
Sources
- 8-K Filing — NEOGEN CORP (NEOG) — SEC EDGAR